NAMS250117C20000
- 6.21
- 0.000.00%
NewAmsterdam Pharma Newsroom
NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.07 Million in Common Stock
Positive Outlook for NewAmsterdam Pharma Driven by Strong Financial Position and Promising Obicetrapib Trial Results
NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$4.86 Million in Common Stock
Menarini Group Announces Positive Topline Data From Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib With Ezetimibe 10 Mg
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
NewAmsterdam Pharma(NAMS.US) 10% Shareholder Sells US$11.74 Million in Common Stock
NewAmsterdam Pharma 12.12M Share Secondary Priced at $24.50
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NewAmsterdam Pharma Is Maintained at Sector Outperform by Scotiabank
NewAmsterdam Pharma Price Target Raised to $47.00/Share From $35.00 by Scotiabank
NewAmsterdam Pharma Analyst Ratings
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $47
We're Not Very Worried About NewAmsterdam Pharma's (NASDAQ:NAMS) Cash Burn Rate
Top 3 Health Care Stocks That May Collapse This Quarter
Express News | New Amsterdam Invest NV : Scotiabank Raises Target Price to $47 From $35
Express News | NewAmsterdam Pharma Commences $300M Public Offering Of Ordinary Shares And Pre-Funded Warrants
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $46
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Buy Rating on NewAmsterdam Pharma: Promising Phase 3 Results and Increased Price Target